(Q45865616)

17 December 2017

title

Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121. (English)

1 reference

17 December 2017

1 reference

1 reference

1

Philippe Taupin

1 reference

17 December 2017

language of work or name

English

0 references

publication date

15 December 2010

1 reference

17 December 2017

Expert Opinion on Therapeutic Patents

published in

1 reference

17 December 2017

volume

21

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

111-114

1 reference

17 December 2017

Natural history of multiple sclerosis: a unifying concept

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Natural history of multiple sclerosis: risk factors and prognostic indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Age at disability milestones in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Temporal trends in the incidence of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Mitoxantrone: a review of its use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

The value of conventional high-field MRI in MS in the light of the McDonald criteria: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Cerebrospinal fluid biomarkers in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Role of the Bp35 cell surface polypeptide in human B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Rituximab for the treatment of diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Pathogenesis and Treatment of Anti-MAG Neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Adult neurogenesis and neural stem cells as a model for the discovery and development of novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

Neurogenic drugs and compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.530253

10.1517/13543776.2011.530253

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

21155688

1 reference

17 December 2017